Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research demonstrating the strength of the company’s cardiovascular franchise at the American Heart Association’s (AHA) annual Scientific Sessions, taking place in-person and virtually November 5-7, 2022. Findings from clinical, patient-reported outcomes and real-world studies will be presented across the cardiovascular portfolio
PRINCETON, N.J.--(BUSINESS WIRE)--Nov 2, 2022--
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research demonstrating the strength of the company’s cardiovascular franchise at the American Heart Association’s (AHA) annual Scientific Sessions, taking place in-person and virtually November 5-7, 2022. Findings from clinical, patient-reported outcomes and real-world studies will be presented across the cardiovascular portfolio. Notably, one abstract from the CAMZYOS ® (mavacamten) development program was accepted as a featured science presentation demonstrating advancements in the treatment of obstructive hypertrophic cardiomyopathy (HCM).
“The AHA annual Scientific Sessions is an important congress for us to share new data that is adding to the growing body of evidence demonstrating the continued positive, long-term impact our treatments are having for cardiovascular patients globally,” said Roland Chen, MD, senior vice president and head of cardiovascular development, Global Drug Development at Bristol Myers Squibb. “We continue to pursue the development of innovative, safe, effective and durable treatment options that improve patients’ lives, and are proud to showcase further analysis from our programs in obstructive hypertrophic cardiomyopathy and thrombosis.”
Key presentations include: